Zhilin Hou

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 7

Top Topics

Room Temperature

Top Venues

Dalton transactions (Cambridge, England : 2003)

RSC medicinal chemistry

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Zhilin Hou, Allison S Vanecek, Jetze J Tepe, Aaron L Odom
Synthesis, structure, properties, and cytotoxicity of a (quinoline)RuCp + complex. Dalton transactions (Cambridge, England : 2003) 52 (3) (2023)
Zhilin Hou, Allison S Vanecek, Jetze J Tepe, Aaron L Odom
Synthesis, structure, properties, and cytotoxicity of a (quinoline)RuCp + complex. Dalton transactions (Cambridge, England : 2003) 52 (3) (2023)
Zhilin Hou, Allison S Vanecek, Jetze J Tepe, Aaron L Odom
Synthesis, structure, properties, and cytotoxicity of a (quinoline)RuCp + complex. Dalton transactions (Cambridge, England : 2003) (2022)
Zhilin Hou, Lizbeth Lockwood, Di Zhang, Christopher J Occhiuto, Linqing Mo, Kelly E Aldrich, Hayden E Stoub, Kathleen A Gallo, Karen T Liby, Aaron L Odom
Exploring structural effects in a new class of NRF2 inhibitors. RSC medicinal chemistry 14 (1) (2022)
Zhilin Hou, Lizbeth Lockwood, Di Zhang, Christopher J Occhiuto, Linqing Mo, Kelly E Aldrich, Hayden E Stoub, Kathleen A Gallo, Karen T Liby, Aaron L Odom
Exploring structural effects in a new class of NRF2 inhibitors. RSC medicinal chemistry 14 (1) (2022)
Zhilin Hou, Lizbeth Lockwood, Di Zhang, Christopher J Occhiuto, Linqing Mo, Kelly E Aldrich, Hayden E Stoub, Kathleen A Gallo, Karen T Liby, Aaron L Odom
Exploring structural effects in a new class of NRF2 inhibitors. RSC medicinal chemistry 14 (1) (2022)
Di Zhang, Zhilin Hou, Kelly E Aldrich, Lizbeth Lockwood, Aaron L Odom, Karen T Liby
A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy. Molecular cancer therapeutics 20 (9) (2021)